title: [Primary study of the recombinant immunotoxin DT390-mRantes in EAE therapy].
abstract: OBJECTIVE
  To construct a novel eukaryotic expression plasmid including the recombinant immunotoxin DT390-mRantes and treat experimental autoimmune encephalomyelitis (EAE) in mice.
  
  
  METHODS
  EAE in C57BL/6 mice were induced by the extracted MBP. The mRantes fragment was inserted into the eukaryotic expression plasmid SRalpha containing DT390. Then cationic liposome-embedded plasmid DNA was injected into the muscles of the hind-limbs in mice. The effect of DT390-mRantes was evaluated by observing clinical symptoms, pathological changes of brain, relative cytokine of peripheral blood, and the proportion of T cells and B cells.
  
  
  RESULTS
  The recombinant immunotoxin DT390-mRantes was successfully constructed. Compared the mice in treated group with those in untreated group the clinical symptoms of EAE were alleviated, the infiltration of inflammatory cells were decreased, the IFN-gamma level was fallen, and the ratio of T/B cells was decreased.
  
  
  CONCLUSIONS
  The recombinant immunotoxin DT390-mRantes has distinct effects on EAE in mice, which may be used for beneficial reference to the therapy of MS.
authors.affiliation: Department of Material Evidence School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China. yijia781021@tom.com
authors.forename: Yi
authors.initials: Y
authors.lastname: Jia
authors.forename: Hong
authors.initials: H
authors.lastname: Li
authors.forename: Wen-Jie
authors.initials: WJ
authors.lastname: Chen
authors.forename: Mei-Li
authors.initials: ML
authors.lastname: Lu
authors.forename: Ming-Yuan
authors.initials: MY
authors.lastname: Li
authors.forename: Zhong-Hua
authors.initials: ZH
authors.lastname: Jiang
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D018946:Chemokine CCL5 / Q000235:genetics*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D005260:Female; D005434:Flow Cytometry; D007150:Immunohistochemistry; D016233:Immunotherapy, Active / Q000379:methods*; D000922:Immunotoxins / Q000235:genetics / Q000627:therapeutic use; D007371:Interferon-gamma / Q000378:metabolism; D008081:Liposomes / Q000737:chemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D010957:Plasmids / Q000235:genetics / Q000276:immunology; D011897:Random Allocation; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism
chemical_list: D018946:Chemokine CCL5; D000922:Immunotoxins; D008081:Liposomes; D011994:Recombinant Proteins; D007371:Interferon-gamma